ClinicalTrials.gg
RecruitingNCT06153836Updated Oct 2, 2026

Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction

A Phase 2 interventional study of Neurotization Procedure and Questionnaire Administration in Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage IIA Breast Cancer AJCC v8, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by Mayo Clinic · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 2, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Breast Carcinoma In Situ by Mayo Clinic — 3 open to participants now, 3 under way, none of them phase 3. Breast Carcinoma In Situ · Mayo Clinic.

Started
2023
with 2 others
Phase 2
5 of 14
2 open now
Registered
12th of 14
by date

Among the 14 studies in Breast Carcinoma In Situ by Mayo Clinic, this one is one of 3 that started in 2023, is one of 5 in phase 2, and was the 12th registered.

Breast Carcinoma In Situ

190 studies on the registry are indexed under Breast Carcinoma In Situ; 25 are open to participants now.

Browse Breast Carcinoma In Situ studies →

Open to participants now

3 of the 14 studies in Breast Carcinoma In Situ by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 23 Breast Carcinoma In Situ studies recruiting now, 17 (74%) set no upper age limit and 4 (17%) stop at 75 or younger; 1 takes children under 18; 3 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Breast Carcinoma In Situ by Mayo Clinic, or all of them as a file.
02

Study summary

This phase II trial tests the willingness of patients undergoing nipple sparing mastectomy (NSM) to enroll in a randomized study of NSM with or without neurotization of the nipple areolar complex (NAC). This trial also compares patient reported outcomes, including quality of life and breast and NAC sexual functionality, for patients undergoing NSM with or without neurotization of the NAC. NSM is a standard practice option for patients undergoing preventative mastectomy, but many report dissatisfaction with decreased nipple sensation. Neurotization is a surgical technique using a nerve graft in an attempt to restore NAC sensation. Neurotization during NSM and reconstruction may restore NAC sensation and improve quality of life in breast cancer patients.

Read the detailed description

PRIMARY OBJECTIVE:

I. To determine willingness of patients undergoing NSM to enroll in a randomized trial of NSM with or without neurotization.

SECONDARY OBJECTIVES:

I. To compare patient reported outcomes, including quality of life and breast and NAC sexual functionality, for patients undergoing NSM with or without neurotization.

II. To compare NAC sensation at 12 months in patients undergoing NSM with or without neurotization.

III To determine rate of mastectomy skin flap necrosis following NSM via the skin ischemia and necrosis (SKIN) score.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo standard of care NSM on study.

ARM II: Patients undergo neurotization during standard of care NSM on study.

After completion of study intervention, patients are followed at 14 days and at 6, 12 and 24 months postoperatively.

03

Conditions studied

  • Anatomic Stage 0 Breast Cancer AJCC v8
  • Anatomic Stage I Breast Cancer AJCC v8
  • Anatomic Stage IIA Breast Cancer AJCC v8
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patients age >= 18
  • (ECOG) performance status of 0, 1, or 2
  • Planned nipple sparing mastectomy (NSM)
  • Ideal NSM candidates would meet the following criteria:

    • Cup size A-C
    • \<34
    • Ptosis grade \< 2
    • Clinical stage 0 - T2N0
    • Final planned implant volume \< 400cc
    • Inframammary or lateral mammary incision
    • Tumor > 0.5cm from the nipple areolar complex (NAC)
    • No prior breast reduction, mastopexy, or periareolar incisions on side of planned NSM
    • No prior breast radiation on side of planned NSM
    • Tumor \<0.5cm from NAC (including suspicious calcifications or MRI enhancement)
    • No planned post mastectomy radiation (PMRT)
    • No nicotine use within 4 weeks of surgical date

Exclusion criteria

Exclusion Criteria:

  • Planned autologous reconstruction (immediate or delayed)
  • Pregnancy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Active comparator
    ARM I (control)

    Patients undergo standard of care NSM on study.

    Other: Questionnaire Administration · Procedure: Subcutaneous Mastectomy

  • Experimental
    ARM II (neurotization)

    Patients undergo neurotization during standard of care NSM on study.

    Procedure: Neurotization Procedure · Other: Questionnaire Administration · Procedure: Subcutaneous Mastectomy

Interventions

  • ProcedureNeurotization Procedure

    Undergo placement of nerve graft

    Also known as: Nerve Regeneration Procedure

  • OtherQuestionnaire Administration

    Ancillary studies

  • ProcedureSubcutaneous Mastectomy

    Undergo standard of care NSM

    Also known as: Nipple-Sparing Mastectomy

06

What researchers measure

Primary outcomes

  1. Percentage of patients undergoing nipple sparing mastectomy (NSM) to enroll in a randomized trial of NSM with or without neurotization

    Will calculate the proportion of eligible patients who opt to take part in the study. Additionally, will descriptively analyze and report the specific factors that influenced patients' decisions to participate, with the aim of identifying and addressing any obstacles encountered.

    Time frame: Up to 2 years

Secondary outcomes

  1. Chest physical well-being

    Measured using the BREAST-Q© scored on a 3-point Likert scale where 1=None of the time and 3=All of the time. Higher scores indicate poorer chest physical well-being.

    Time frame: At baseline and up to 12 months

  2. Psychosocial well-being

    Measured using the BREAST-Q© scored on a 5-point Likert scale where 1=None of the time and 5=All of the time. Higher scores indicate poorer psychosocial well-being.

    Time frame: At baseline and up to 12 months

  3. Sexual well-being

    Measured using the BREAST-Q© scored on a 5-point Likert scale where 1=None of the time and 5=All of the time. Higher scores indicate poorer sexual well-being.

    Time frame: At baseline and up to 12 months

  4. Patient reported amount of sensation in nipple areolar complex (NAC) and breast

    Patient reported amount of sensation in nipple areolar complex (NAC) and breast will be will be assessed using a 5-item sensation questionnaire with 5 options to answer each question. Examples of answers include a range from Very unpleasant to Very pleasant or Unimportant to Very Important. Results will be reported descriptively.

    Time frame: At baseline and up to 12 months

  5. Patient reported significance of breast or NAC for sexuality

    Patient reported significance of breast or NAC for sexuality will be assessed using a 5-item Significance of Breast or Nipple Areolar Complex for Sexuality Questionnaire with 5 options to answer each question: Not at all, A little bit, Somewhat, Quite a bit, or Very much. Results will be reported descriptively.

    Time frame: At baseline and up to 12 months

  6. Tactile sensitivity scores

    Measured using Semmes Weinstein monofilament test. Scores will be averaged for each patient across all breast/ NAC measurements and summarized in terms of mean, standard deviation, median, and range. The ordinal score at each of the sites will also be summarized in terms of median and range. Frequency and type of missing data will be summarized.

    Time frame: At baseline and up to 12 months

  7. Incidence of adverse events (AEs)

    AEs will be scored using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) and will be summarized within arms by reporting the number and percentage of patients for each AE. The maximum grade for each type of AEs will be recorded for each patient and frequency tables will be reviewed to determine overall patterns. The frequency and type of solicited AEs experienced in each arm will also be reported.

    Time frame: At 12 months

  8. Mastectomy skin flap necrosis

    Incidence of mastectomy skin flap necrosis will be assessed using the skin ischemia necrosis (SKIN) score, as recorded by clinical staff. Necrosis is defined as any depth SKIN score of C or D and surface area \>1.

    Time frame: At 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jul 2028, 55 months after the start.

Of 21 phase 2 interventional studies under Breast Carcinoma In Situ, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 75. This study's planned 55 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Nov 2026 → Jul 2028 and completion Nov 2026 → Jul 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 22, 2023
First posted
Dec 1, 2023
StartActual
Dec 5, 2023
Primary completionEst.
Jul 19, 2028was Nov 2026
CompletionEst.
Jul 19, 2028was Nov 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Nov 10, 2026→Jul 19, 2028
Oct 2, 2026
Study completion
Nov 10, 2026→Jul 19, 2028
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Primary completion Nov 10, 2026→Jul 19, 2028
    Study completion Nov 10, 2026→Jul 19, 2028
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06153836
Lead sponsor
Mayo Clinic
Responsible party
Sponsor
First posted
Dec 1, 2023
Start date
Dec 5, 2023
Primary completion
Jul 19, 2028 (estimated)
Completion
Jul 19, 2028 (estimated)
Last update
Oct 2, 2026

Study contacts

Clinical Trials Referral Office
Contact
mayocliniccancerstudies@mayo.edu
855-776-0015
James W. Jakub, M.D.
principal investigator · Mayo Clinic
Olivia S. Ho, M.D., M.S.
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion